Introduction {#S1}
============

Atypical hemolytic uremic syndrome (aHUS) is a rare but life-threatening disease. It is characterized by the dysregulation of the complement alternative pathway due to mutations of the genes encoding complement factors and regulators, or autoantibodies directed against the regulator factor H (FH) ([@B1], [@B2]). Autoimmune aHUS usually evolves in children and adolescents and accounts for approximately 10% of all aHUS cases in the Western world ([@B3]--[@B5]). However, in an Indian cohort an incidence rate of 56% was reported, but the reason for this high frequency of autoantibody positivity remains to be explained ([@B6]). Autoimmune aHUS has a high relapse rate and risk of developing end stage renal disease ([@B7]--[@B10]).

Factor H consists of 20 homologous domains termed short consensus repeats (SCRs). It acts as a regulator of the complement alternative pathway ([@B11]--[@B13]) by exerting its cofactor and decay-accelerating activities through the N terminal SCR domains 1--4 and host discrimination (*via* sialic acid/glycosaminoglycan and C3b/C3d binding) through the C-terminal domains 19--20 ([@B14], [@B15]). The key characteristics of autoimmune aHUS are the FH autoantibodies that block FH ([@B16]), upon which the regulator is unable to restrain complement activation on host tissues. The autoimmune form of aHUS is linked to the deficiency of complement factor H-related (CFHR) proteins 1 and 3 ([@B17]) that have a yet unexplained role in the pathogenesis. While the frequency of heterozygous deletion of CFHR1 is similar in healthy individuals and aHUS patients, homozygous deletion of this protein is strongly associated with aHUS and was described in 82--88% of patients with FH autoantibodies ([@B4], [@B6], [@B18]--[@B20]). CFHR1 has a similar domain structure to that of FH, and SCR domain 5 of CFHR1 differs from FH SCR domain 20 in only two amino acids, whereas CFHR1 domain 4 and FH domain 19 are exactly the same ([@B21]). FH carries a serine at amino acid position 1191 and a valine at position 1197, while CFHR1 contains a leucine and an alanine at the corresponding positions (residue 290 and 296). Together with other CFHRs and FH-like protein 1, they form the FH protein family ([@B22]). Although CFHR1 competes with FH in C3b binding ([@B23]) and may neutralize the FH autoantibodies *in vitro* ([@B24]), it is currently unknown whether CFHR1 has a causative role in antibody production and how its deletion may contribute to the manifestation of aHUS.

Whereas the functional consequence of the antibody binding to FH is widely studied, little is known about the fine epitope specificity of the autoantibodies. Based on recent observations ([@B25], [@B26]), we hypothesized that the major antibody binding site is located on SCR domains 19--20 of FH, although other domains may also be recognized by aHUS-associated FH autoantibodies ([@B19], [@B25], [@B27]). Despite recent progress in the structural exploration of antibody binding to the folded FH domains ([@B27], [@B28]), we lack detailed knowledge of where the aHUS-associated FH epitopes are localized at the amino acid level. To answer this question, we performed fine epitope mapping using point-mutated FH domains and linear epitope mapping with overlapping synthetic peptides.

We further compared the epitopes of the autoantibodies on FH versus CFHR1. Our hypothesis was that aHUS-specific linear epitopes are also present on CFHR1, based on its homology to FH and its described cross-reactivity with the FH autoantibodies ([@B24]).

Materials and Methods {#S2}
=====================

Patients and Serum Samples {#S2-1}
--------------------------

For linear epitope mapping experiments leftover sera of children with treatment-naive, acute autoimmune aHUS were used. Inclusion criteria were as follows: presence of HUS \[evidence of microangiopathic hemolytic anemia, evidence of renal injury, and evidence of thrombocytopenia (\<150 G/L)\] with an anti-FH autoantibody level \>110 AU/ml ([@B29]). Exclusion criteria: HUS in convalescence (lack of hemolysis and lack of thrombocytopenia) and/or ongoing active treatment of HUS (either of the following: plasmapheresis, corticosteroids, cyclophosphamide, and rituximab) and/or lack of available serum sample (Figure S1 in Supplementary Material). Finally, eight patients could be enrolled in our investigations of which seven of eight had convalescence phase sample available (Table [1](#T1){ref-type="table"}). Convalescence phase serum collection was done 6--12 months after the termination of any specific treatment of the patients. Samples of control children (median age of 9 years) were collected from leftover serum specimens from patients, who were admitted to the 1st Department of Pediatrics at Semmelweis University upon distinct indications, and detailed laboratory analysis (including inflammatory markers) did not reveal pathological findings. All control children were negative (below cutoff) for anti-FH. Patient enrollment was closed in September 2016. This study was carried out in accordance with the Helsinki Declaration, the study was approved by the Ethics Committee on Human Research in Budapest (8361-1/2011-EKU), and written informed consent was obtained from each subject.

###### 

**Patients with the diagnosis of atypical HUS enrolled in this study who had positive ELISA results for anti-factor H (FH) antibodies (\>110 AU/ml) at the time of presentation**.

  Patient code   Age at disease onset (years)   Gender   FH autoantibody level in the acute phase of HUS (AU/ml)   FH autoantibody level in the convalescence phase of HUS (AU/ml)   MLPA analysis of CFHR1 and CFHR3
  -------------- ------------------------------ -------- --------------------------------------------------------- ----------------------------------------------------------------- -------------------------------------------------------------------
  P1             6.5                            Male     10,067                                                    136                                                               Homozygous deletion of CFHR1 and CFHR3
  P2             8.5                            Male     2,190                                                     125                                                               Homozygous deletion of CFHR1 and CFHR3
  P3             10.5                           Female   1,306                                                     93                                                                Homozygous deletion of CFHR1 and CFHR3
  P4             8                              Female   2,221                                                     99                                                                Homozygous deletion of CFHR1 and heterozygous deletion of CFHR3
  P5             8                              Male     2,725                                                     213                                                               Heterozygous deletion of CFHR1 and heterozygous deletion of CFHR3
  P6             8                              Male     209                                                       55                                                                Homozygous deletion of CFHR1 and CFHR3
  P7             11                             Male     329                                                       89                                                                Homozygous deletion of CFHR1 and CFHR3
  P8             11                             Female   9,152                                                     No sample available                                               Homozygous deletion of CFHR1 and CFHR3

*Major clinical characteristics and results of multiplex ligation dependent-probe amplification (MLPA) are listed*.

Determination of the FH Autoantibody Level in Patient Sera {#S2-2}
----------------------------------------------------------

Serum anti-FH IgG level was determined by an ELISA method described previously ([@B1]), with some modifications applied as follows. Nunc MaxiSorp plates (Nunc, Roskilde, Denmark) were coated with 1 μg/ml purified human FH (Calbiochem, San Diego, CA, USA). Serum samples were added at a dilution of 1:200 following blocking with PBS-1% BSA. As secondary antibody a rabbit anti-human IgG-HRP was used (Dako, Glostrup, Denmark) followed by the detection of bound IgG using 3,3′,5,5′-tetramethylbenzidine (TMB) with optical density (OD) read at λ = 450 nm (reference at λ = 620 nm). The assay was calibrated to a sample obtained as a kind gift from Dr. Dragon-Durey, and the cutoff value (\>110 AU/ml) was determined according to the mean + 2 SD of 80 healthy individuals.

Peptide Synthesis for Epitope Mapping {#S2-3}
-------------------------------------

Fifteen amino acid-long peptides of FH SCR domains 19--20 and the CFHR1 region homolog to that of 1177--1211 on FH (amino acids 276--310 of CFHR1) were synthesized in duplicates on Mimotopes NCP gears (Clayton, VIC, Australia) according to Geysen's method ([@B30]) as previously described ([@B31]). As control of peptide synthesis, three peptides were subjected to amino acid analysis, and the correct amino acid composition was verified. The amino acid sequence of each syntehtic peptide, as well as further details of the peptide synthesis are listed in Table S1 and Data Sheet S1 in Supplementary Material.

Antibody Binding to the Immobilized Synthetic Peptides of FH and CFHR1 {#S2-4}
----------------------------------------------------------------------

Serum antibody binding to overlapping synthetic peptides was determined by a modified ELISA as described previously ([@B32]). As a negative control peptide the heat shock protein (HSP) 60 fragment 480--489 was applied, based on our earlier observations, since this peptide showed the lowest binding with human sera in our past experiments ([@B32]). In the current experiments, we optimized the serum dilution to 1:1,000 and used a TMB detection system with OD read at λ = 450 nm (reference at λ = 620 nm). Data were normalized by the following formula: OD~sample~/OD~min~, where OD~sample~ is the mean of duplicate OD values of the test samples and OD~min~ represents the mean binding to the negative control HSP480--489 peptide. The interpretation of such a ratio can be done as fold changes over background. Epitope specific autoantibody binding in the acute phase and in convalescence serum samples is presented as OD~sample~/OD~min~ values, too.

Antibody Binding to Recombinant FH 19--20 Mutants {#S2-5}
-------------------------------------------------

Determination of serum antibody binding to the recombinant FH domains 19--20 displaying various single amino acid changes was performed with an ELISA-based method as previously described ([@B25], [@B26]).

Location of the Epitopes and Point Mutations on the Folded FH and CFHR1 Structures {#S2-6}
----------------------------------------------------------------------------------

We analyzed the localization of the epitopes on the crystal structures of FH domains 19--20 \[DOI:10.2210/pdb2g7i/pdb ([@B33])\] using the SWISS-PDB Viewer software \[([@B34]), <http://www.expasy.org/spdbv/>\].

Statistical Analysis {#S2-7}
--------------------

Data analysis was performed in the GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA, USA, [www.graphpad.com](www.graphpad.com)). Autoantibody binding to the mutant FH domain constructs was compared to the wild type FH domains 19--20 with one-sample Wilcoxon signed-rank test. Anti-FH autoantibody binding in the independent samples was tested with Mann--Whitney test, whereas Wilcoxon matched-pairs signed-rank test was used to compare the acute and convalescence phase-autoantibody binding.

Results {#S3}
=======

Localization of Linear Autoantibody Epitopes on FH {#S3-1}
--------------------------------------------------

The synthetic peptides (Table S1 in Supplementary Material) were used for ELISA studies to determine autoantibody binding. Reactivity of serum autoantibodies to the synthetic peptides of 10 control children and 8 acute aHUS patients is shown in Figure [1](#F1){ref-type="fig"}. All serum samples of the eight aHUS patients were taken before the initiation of plasmapheresis; however, two of our patients received fresh frozen plasma prior to sampling. Peptides with a significantly increased autoantibody binding (patients versus control, Mann--Whitney test) contained either amino acids 1157--1171, located within FH domain 19, or amino acids 1177--1191 or 1207--1226, located within FH domain 20. The highest average binding was found with peptides containing residues 1212--1226. Even though average autoantibody binding to the linear peptides is shown, it is noteworthy that all three of the linear epitopes displayed increased autoantibody binding in the acute phase sera of every child.

![**Relative binding of serum factor H (FH) autoantibodies to the synthetic FH peptides in control patients and in acute phase of atypical hemolytic uremic syndrome**. The mapped FH domains were short consensus repeat (SCR) 19 **(A)**, SCR 20 **(B)** and the fragment of CFHR1 SCR domain 5 homolog to that of FH amino acids 1177--1211 **(C)**. We analyzed the sera of 10 control children (black bars) and 8 children in the acute phase of HUS (white bars), data represent mean of relative autoantibody binding of each group with SEM. Relative autoantibody binding is expressed as the ratio of OD~sample~/OD~min~, where OD~sample~ is the mean of duplicate optical density (OD) values of the test samples and OD~min~ is the mean binding to control HSP480--489 peptide that showed the lowest binding in our experiments. Numbering on the *x* axis represents the initial and final amino acid of each tested peptide. Difference in autoantibody binding to the indicated peptides was determined with Mann--Whitney test. Statistical significance is indicated by asterisks (\**p* \< 0.05; \*\**p* \< 0.01).](fimmu-08-00302-g001){#F1}

Epitope Specific Autoantibody Binding in Convalescence versus the Acute Phase of aHUS {#S3-2}
-------------------------------------------------------------------------------------

We had the opportunity to test convalescence phase sera from seven of eight patients who were followed-up on a monthly basis after termination of therapy. Therapy of the children included plasmapheresis, immunosuppression with corticosteroids or cyclophosphamide, and/or rituximab. The convalescence phase samples were collected after a minimum follow-up period of 6 months in convalescence, during which the patients received no immunomodulation or any forms of plasma therapy. Albeit no relapse occurred in any of the enrolled patients, the level of free anti-FH IgG remained low-titer positive in three out of seven cases (Table [1](#T1){ref-type="table"}). The epitope recognition pattern of the autoantibodies remained similar in the convalescence phase compared to what we had observed at the acute disease onset although the signals were weaker (Figure [2](#F2){ref-type="fig"}). The observed decline reached statistical significance by one of the peptides (peptide 1177--1191) although in case of all peptides a decrease of at least 25% was observed at the level of group mean.

![**Epitope specific relative anti-factor H autoantibody binding to the linear epitopes in convalescence (gray bars) versus the acute phase (white bars) of atypical hemolytic uremic syndrome**. The mapped FH domains were short consensus repeat (SCR) 19 **(A)**, SCR 20 **(B)** and the fragment of CFHR1 SCR domain 5 homolog to that of FH amino acids 1177-1211 **(C)**. Analysis of seven patients is shown as mean and SEM of the relative autoantibody binding (OD~sample~/OD~min~) of each group, where OD~sample~ is the mean of duplicate optical density (OD) values of the test samples and OD~min~ is the mean binding to control HSP480--489 peptide. Numbering on the *x* axis shows the initial and final amino acid of each tested peptide. Statistical analysis for the difference in autoantibody binding to the indicated peptides was performed using Wilcoxon matched-pairs signed-rank test (\**p* \< 0.05).](fimmu-08-00302-g002){#F2}

Comparison of FH Autoantibody Binding to Linear Epitopes on CFHR1 and FH {#S3-3}
------------------------------------------------------------------------

Since seven of our patients carried a homozygous and one a heterozygous deletion of CFHR1, we synthesized overlapping peptides of the region containing the two residues which are different in FH and CFHR1 (Table S1 in Supplementary Material). Supporting our observations with FH, we identified significant autoantibody binding to peptide 276--290 of CFHR1, which covered the exact same location as the previously identified autoantibody epitope on FH (peptide 1177--1191). Moreover, the serine--leucine exchange did not influence autoantibody binding since a very similar extent of binding was observed for the homologous peptides (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

Fine Epitope Mapping Using FH Domains 19--20 Displaying Point Mutations {#S3-4}
-----------------------------------------------------------------------

We applied various recombinant FH19--20 constructs displaying single amino acid changes associated with aHUS to validate the results of the linear epitope mapping on the folded FH domains. To locate potential regions on FH19--20 where amino acid changes affect FH autoantibody binding (as compared to recombinant wild type FH), 14 different constructs were tested in ELISA (Figure [3](#F3){ref-type="fig"}) using serum samples of three patients. We observed the highest decrease in anti-FH binding in case of FH 19--20 construct displaying mutation at amino acid position 1188. A distinct antibody binding epitope appeared between amino acids (aa)1183--1198 with a symmetric gradual decline in antibody binding toward aa1188. Additional positions where anti-FH binding was decreased were detected on domain 19 (aa1139 and aa1157) and the C-terminal end of domain 20 (aa1210 and aa1215) concordant to the location of the identified linear epitopes.

![**Factor H (FH) autoantibody binding to single amino acid-substituted recombinant FH short consensus repeat (SCR) domains 19--20 compared to the wild type protein**. The amino acid substitutions are indicated on the *x* axis with capital letters, and numbers marking their location (gray bars) compared to the recombinant wild type FH SCRs 19--20 (striped bar). Binding is expressed in percent relative to that of the wild type (100%, intermittent line). We tested the sera of three patients in the acute phase of atypical hemolytic uremic syndrome; mean and SEM of three independent experiments are shown. Statistical analysis was performed with the one-sample Wilcoxon signed-rank test; statistical significance is indicated by asterisks (\**p* \< 0.05; \*\**p* \< 0.01).](fimmu-08-00302-g003){#F3}

Location of the Identified Linear FH Epitopes on Crystal Structure of FH {#S3-5}
------------------------------------------------------------------------

We visualized the location of the linear epitopes in the tertiary structure of FH using its structure obtained from the Protein Data Bank (Figure [4](#F4){ref-type="fig"}). We also positioned the generated point mutations on the folded domains of the protein (Figure [4](#F4){ref-type="fig"}A). In the steric conformation, epitope 1157--1171 appears as a linear segment in the hinge region between FH domains 19 and 20, while epitopes 1177--1191 and especially 1207--1226 are in close sterical proximity with the C-terminal end of peptide 1157--1171. The homologous peptide on CFHR1 (276--290) had a similar structure to that of FH aa1177--1191 (data not shown).

![**Folded structure of complement factor H (FH) short consensus repeat domains 19--20**. Panels represent the ribbon model of the molecule obtained from the Protein Data Bank (pdb*2g7i*). Linear epitopes of the FH autoantibodies are highlighted with orange \[amino acid (aa)1157--1171, aa1177--1191, and aa1207--1226\], where the initial and final aa of each segment is indicated with black numbers. Arrowheads point toward the C-terminal end of the proteins. **(A)** The location of the generated point mutations is displayed as colorful spheres on the backbone of the protein, with white numbers indicating their location and colors their effect on autoantibody binding by FH (red: significantly decreased binding when the aa substitutions is present; green: no significant effect on binding). **(B)** Colorful spheres refer to aa forming the C3b ([@B14], [@B35]) (light blue) and sialic acid ([@B15]) (dark blue) binding sites of the molecule. Numbers within the spheres show the location of each aa.](fimmu-08-00302-g004){#F4}

Discussion {#S4}
==========

In this study, we identified for the first time three linear, extended autoantibody binding epitopes on FH and one on CFHR1. These epitopes were recognized by both acute phase and convalescence phase serum autoantibodies of aHUS patients. We propose that the autoantibody binding site formed by the linear epitopes in the tertiary structure overlaps not only with the reported clustering of aHUS-associated FH mutations (Figure [4](#F4){ref-type="fig"}A) but also with the previously described location of FH fractions necessary for sialic acid and C3b binding (Figure [4](#F4){ref-type="fig"}B).

The epitope identified on CFHR1 confirms the previously observed cross-reactivity toward FH ([@B18], [@B24]), which may underline the role of CFHR1 in aHUS pathogenesis.

Results of the mutant domain and linear epitope mapping were concurrent on both domains 19 and 20 of FH. In line with published observations ([@B25]), we detected the biggest reduction in domain recognition when we introduced mutations to amino acids in the 1183--1198 region (Figure [3](#F3){ref-type="fig"}). This distinct binding motif overlaps the location of linear epitope 1177--1191, while on the C-terminal end of domain 20 the linear epitope 1207--1226 corroborates the reduced domain recognition of R1210A and R1215Q (Figure [4](#F4){ref-type="fig"}A).

The location of the identified epitopes corresponds to the known impairment of FH function in autoimmune aHUS. On one hand, the mutations Q1139A and two of the linear epitopes (1157--1171; 1177--1191) affect amino acids involved in C3b binding ([@B14], [@B35]), which matches the observed reduced C3b recognition of FH in the presence of autoantibodies ([@B16]). On the other hand, the epitope on the C-terminal end of domain 20 covers the reported heparin and sialic acid binding sites of the molecule ([@B14], [@B15]). This suggests a dwindled access of host surface sialic acids to autoantibody-bound FH, which could lead to subsequent loss of host recognition by the regulator. The simultaneous interference with both C3b binding and self-discrimination creates a basis for complement over-activation on host surfaces, most probably due to the inhibition of the C3b--sialic acid--FH complex formation as concluded by others ([@B36]). FH and related proteins are known to interact with the soluble pattern recognition molecules, pentraxins. The pentraxin-3 binding site on SCR20 of FH was recently located to involve amino acids 1180--1186 and 1198--1204 ([@B37]), which partially overlaps the identified autoantibody specific epitope 1177--1191. Due to inhibition of pentraxin binding, autoantibody-blocked FH may be unable to exert its complement regulatory activity at local sites of activation.

To outline the binding preference of the autoantibodies, we chose to include synthetic peptides of CFHR1 in the linear epitope mapping. Surprisingly, we detected a similar autoantibody recognition pattern on CFHR1 to that of FH in both controls and aHUS patients. The FH autoantibody specific epitope on CFHR1 (276--290) showed the same extent of autoantibody binding as its homolog on FH, although seven of our patients tested deficient for CFHR1. This observation is in line with the described cross-reactivity and neutralizing effect on CFHR1 of FH autoantibodies ([@B18], [@B24]), even though the C-terminal domains of CFHR1 are described to have lower avidity to the autoantibodies than those of FH ([@B26]). The concept that an induced neoepitope on FH similar in structure to CFHR1 drives autoantibody production ([@B26]) could explain the equivalent autoantibody binding, even though CFHR1 contains a leucine at position 290 instead of the serine present on FH at position 1191. However, as a limitation of our study, the synthetic peptides represented linear autoantibody binding sites with equal accessibility, while under physiological circumstances some of these epitopes may be hidden, especially in the cryptic conformation of FH.

There was a notable difference in the extent of autoantibody binding to the linear epitopes in the individual samples, which matched the FH autoantibody levels of the patients. However, all three of the identified linear epitopes showed increased autoantibody binding compared to the background reactivity in every patient's serum. Although the level of epitope specific antibodies decreased in convalescence, the binding pattern remained the same with autoantibody positivity (\>110 AU/ml) in three of our patients, but no relapse during the follow-up period. This finding, together with the observation that anti-FH autoantibodies might be present in healthy individuals ([@B6]) may further support the concept of a necessary environmental trigger event preceding the manifestation of the disease, not only by the first acute episode but also before relapses.

The identified epitopes are located close to each other on the folded domains of FH. The middle of fragment 1177--1191 protrudes from the surface of the protein (1185--1187 residues are highly accessible), then a few of its C-terminal residues form a short parallel structure with the 1165--1168 residues of the linear structure 1157--1171. The C-terminal epitope 1207--1226 forms a loop, centering in a turn structure of 1219--1222, and the residues of the turn are again close to the 1163--1167 residues of peptide 1157--1171: the C-terminal residues of 1177--1191 and the turn region of 1207--1226 sandwich the middle of the 1157--1171 sequence. This configuration of the linear epitopes overlaps the reported ternary complex of FH, sialic acids and the C3b thioester-containing domain (Figure [4](#F4){ref-type="fig"}B). The recognition of all three of the linear epitopes by the autoantibodies of every patient lets us suspect that wherever the autoantibody binding occurs, it either alters the conformation of this binding site or interferes with C3b and sialic acid recognition by FH through steric hindrance. This hypothesis is also substantiated by the clustering of aHUS-associated FH mutations at this region ([@B26]).

Taken together, we have shown that the aHUS-specific autoantibodies recognize three distinct linear epitopes on FH and one on CFHR1. The linear binding sites on FH are located close to each other in the tertiary structure, which may suggest the formation of a conformational antibody binding site during *in vivo* folding. However, this assumption requires further experimental confirmation. The novelty of this work lies in the testing of autoantibody binding to factory H in a direct way, using synthetic peptides of the regulator and also CFHR1. The presence of the autoantibody binding epitopes was validated with the binding assays performed with recombinant FH domains 19--20 with point mutations. The lack of significant decrease in the epitope specific autoantibody binding to all, but one epitope in the convalescence phase of aHUS indicates the presence of additional factors that trigger relapses. The presence of an autoantibody specific epitope on CFHR1 underlines its role in aHUS pathogenesis, although its exact function is yet to be defined. Observations of this study contribute to the accurate mapping of the autoantibody binding site on FH and CFHR1, which in the long term may help us to design specific inhibitors thus preserving FH function and also to explore in detail the necessary factors involved in aHUS pathogenesis.
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